Abstract Ir(I) complexes of the type [(COD)Ir(NHC)(Py)]PF6 have been exposed as efficient catalysts in the area of hydrogen isotope exchange. More specifically, via an ortho-directed C-H activation process, high levels of deuterium incorporation have been achieved using low levels of catalyst over a range of functionalised aromatic compounds. Additionally, the developed protocol has been extended to include a selected pharmacological target, where chemoselective labelling is observed within such a multifunctional substrate.
Isotopic labelling with heavy hydrogen isotopes (D2 and T2) is widely used as a means to monitor the biological fate of a potential drug molecule. 2 In relation to this, methods that deliver hydrogen isotope exchange (HIE) are of appreciable importance in accessing such isotopically-labelled species, whilst also being central to the provision of analogous deuterated compounds for use as internal standards as aligned with mass spectrometry, 3 for kinetic isotope studies, 4 and for the alteration of reaction pathways in total synthesis. 5 As such, direct, flexible, and selective means of introducing hydrogen isotopes continues to be the focus of considerable research attention. In this regard, studies from our laboratory have shown that a range of iridium complexes of the type [(COD)Ir(IMes)(PR3)]X are very effective homogeneous catalysts which mediate the exchange of hydrogen with deuterium (or tritium) via an ortho-directed C-H activation process. 2c,6 The key to their applicability in this area lies with the ability of such complexes to selectively target unactivated C-H bonds, whilst simultaneously allowing convenient isotope incorporation with the use of, practically convenient, deuterium or tritium gas (Scheme 1). Our developing methodology in this domain allows exchange with high levels of incorporation using low levels of catalyst and encompasses a comprehensive range of substrates including ketone, amide, nitro, and a spectrum of heterocyclic functionality, and, most recently, primary sulfonamides 7 and esters, 6f which were previously less accessible targets. Indeed, the developed series of iridium complexes have emerged to become some of the most active species now known in this area of labelling chemistry.
Scheme 1 Hydrogen isotope exchange process
In addition to an isotopic exchange process, our [(COD)Ir(IMes)(PR3)]X complexes have been shown to perform as effective hydrogenation catalysts, delivering reduced products under notably mild reaction conditions. 8 In relation to this, studies by Nolan et al. have divulged that iridium species with the alternative specific combination of a bulky Nheterocyclic carbene (NHC) and a pyridine ligand represent appreciably robust complexes that are active within both alkene hydrogenation 9 and transfer hydrogenation protocols. 10 In view of these findings, and based on the knowledge that judicious and careful manipulation of the ligands supporting the iridium centre is critical for success within hydrogen isotope exchange processes, we turned our attention to the application of the general class of Ir(NHC)(py) complexes Our initial investigations involved the preparation of catalysts 3a-c 9,10 via the modified preparative procedure shown in Table  1 . In this regard, the desired N-heterocyclic carbene was reacted with readily accessible [(COD)Ir(py)2]PF6, 2, 11 via a simple ligand exchange reaction in toluene. Pleasingly, the desired complexes were obtained in very good chemical yield in every case. Moreover, this procedure allowed the preparation of these extremely stable catalyst species on gram scale. Having successfully prepared complexes 3a-c, we looked to the standard HIE protocol developed within our laboratory for the labelling of a variety of substrates. As shown in Scheme 2, catalysts 3a-c displayed very good levels of efficiency in our labelling protocol. Using only 5 mol% catalyst loading, high levels of deuterium incorporation at the expected orthopositions were achieved for the selected substrates over 16 h. Ketones, amides, pyrazole, and imidazole functionalities were all viable within this system, with catalyst 3c, derived from SIMes, proving the most active in the majority of cases. Notable examples include the labelling of benzamide, 4c; despite this substrate previously requiring extremely high levels of catalyst and delivering variable results, 13a,b complexes 3a-c delivered consistently high isotope incorporations for this substrate within our study. The [(COD)Ir(NHC)(py)]PF6 complex class was also able to deliver very good levels of deuteration with acetanilide, 4f, facilitating isotope exchange in C-H bonds positioned five bonds away from the required coordinating functionality i.e. via a 6-membered metallacyclic intermediate (6-mmi). This process is believed to be energetically more demanding and, as such, often leads to lower levels of deuteration. 6a,d Moreover, the delivery of deuterium labelled heterocyclic derivatives 5g and 5h displays additional versatility and illustrates the overall robustness of this catalytic system. Whilst we believe that the encumbered nature of the iridium centre within this wider catalyst series is key to the high levels of activity shown, 6 we were conscious that these same steric constraints may disfavour the initial coordination of larger and more tetrahedral directing functional units such as sulfonamides. 7 Having stated this, we were able to induce high levels of incorporation within compound 5i, albeit by moving to a much higher catalyst loading of 50 mol%.
Similarly, an increased loading of 10 mol% was required to more effectively deliver deuterated ester 5j at a level of 94% D incorporation under ambient conditions; again, this was a pleasing outcome given the well-documented difficulties arising with such a weakly binding aromatic ester group. 6f,13
At this point, it is important to reflect on the preparation and performance of this [(COD)Ir(NHC)(py)]PF6 complex class and their new application as C-H activation catalysts, as compared to our existing and more well-established [(COD)Ir(IMes)(PR3)]PF6 series. In relation to this, both catalyst classes are readily accessible and provide stable and readily handled species for use in HIE processes. Indeed, access to the NHC/pyridine complexes described here is relatively Scheme 2 HIE reaction scope. 14 Average incorporation into the positions shown over two separate reaction runs; the percentage given refers to the level of D incorporation over the total number of positions shown, e.g. 94% for the two possible positions in 5a indicates 1.88 D incorporation. a Reaction run using 50 mol% catalyst. b Reaction run using 10 mol% catalyst.
Template for SYNLETT © Thieme Stuttgart · New York 2015-10-26 page more direct overall, notwithstanding the requirement for the use of a glove box technique at the outset of the preparative process. 12 With regards to catalyst performance within the described HIE processes, in an overall qualitative sense, the NHC/pyridine complexes generally compare well with our existing NHC/phosphine series, especially when considering, for example, substrates such as acetophenone (4a), benzophenone (4b), and 2-phenylpyrazole (4g). 6a,d Additionally, this current set of catalysts delivered good levels of isotopically-labelled benzamide (5c) across the series, where the [(COD)Ir(IMes)(PR3)]PF6 complexes delivered somewhat more variable results with this primary amide substrate. 6a,d Moreover and as described above, moving to slightly increased catalyst loading, 3c was able to accommodate ester functionality at ambient temperatures, whereas our previous [(COD)Ir(IMes)(PR3)]PF6 systems employed moderately elevated temperatures to deliver similar levels of incorporation in ester containing compounds at lower catalyst loading. 6f Encouraged by the results obtained to this stage, we looked to more fully probe the reaction parameters in an attempt to explore the wider capability of the NHC/pyridine catalyst series within these HIE processes. As such, varying levels of catalyst loading were explored, as well as a study on the reaction rate. Despite lower quantities of catalyst being utilisable in the hydrogen isotope exchange of acetophenone, 4a, 15 it was recognised that a reliable quantity of 5 mol% of the requisite iridium species was optimal over a range of substrates. In addition to these experiments, as shown within Table 2 , we were pleased to realise that our developed labelling protocol was indeed more rapid than anticipated. As detailed, after only 30 minutes, using 5 mol% of SIMes catalyst 3c, comparably high levels of incorporation were achieved with the majority of substrates tested as part of our studies. In contrast, at 30 minutes reaction time the more demanding substrates, benzamide 4c, 2-phenylimidazole 4h, and ethyl benzoate 4j did not deliver the high levels of incorporation obtained over the more prolonged 16 h process.
In an extension of these studies and to further illustrate the capability of catalysts of type 3, we applied the SIMes derived complex 3c in the hydrogen isotope exchange of SanofiSynthélabo's pharmacological target, 6 (Scheme 3). The ability to label fully functionalised drug scaffolds is central to the application of HIE catalysis, especially as aligned to the endeavours of pharmaceutical partners. In this instance we were pleased to obtain 86% D incorporation using 20 mol% of catalyst, albeit over 42 h. Notably, the observed labelling was completely selective, with incorporation occurring at the least hindered site of the complex drug target and as directed by the adjacent amide functionality via a 5-mmi.
Scheme 3 HIE of a pharmaceutical agent, SR 121463.
In summary, we have revealed the escalated capability of complexes of the type [(COD)Ir(NHC)(py)]PF6 within transition metal catalysis. Specifically, such complexes have been shown to perform within an ortho-directed C-H activation and hydrogen isotope exchange process, delivering high levels of deuterium incorporation over a series of functionalised aromatic substrates. The established system displays notable efficacy under mild reaction conditions and over short reaction times. From these studies, catalyst 3c has proven to be the most versatile and broadly applicable of the series applied, and also providing high levels of selective isotopic labelling within a fully functional drug target. With HIE now a key procedure in the optimisation of the drug discovery process, the results presented in this study are of direct value and importance to pharmaceuticals partners. Indeed, ongoing studies within our laboratory have the goal of discovering catalysts that are compatible with increasingly complex organic molecules and alternative drug-like substrates, as well as in the establishment of alternative C−H activation processes in a wider sense.
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